Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of dose and duration optimization of drotrecogin alfa (activated) in severe sepsis
2006-002112-99Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2006
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of drotrecogin alfa in sepsis (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Mean change in protein C level from Study Day 1 to Study Day 7. Started Jun 2006; status: completed.
02
Drugs
drotrecogin alfa
03
Conditions
sepsis
Beyond the preview
Go deeper on 2006-002112-99.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002112-99.